RecruitingPhase IIEN originalLeukemia

Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

NCT06099366Original on ClinicalTrials.gov ↗
⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for high risk acute lymphoblastic leukemia in children and adolescents.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • •Dzieci i młodzież z nowo zdiagnozowaną ostrą białaczką limfoblastyczną, która jest uważana za standardowe ryzyko.
  • •Wiek od 1. do poniżej 10 lat.
  • •Liczba białych krwinek na początku choroby poniżej 50 000/µl.
  • •Brak zajęcia jąder przez chorobę.
  • •Prawidłowa praca nerek (wartości są ustalane indywidualnie dla wieku i płci).

✗ Disqualifies

  • •Przyjmowanie sterydów w ciągu 2 tygodni przed rozpoczęciem badania.
  • •Obecność określonych zmian w chromosomach, które wiążą się z wyższym ryzykiem.
  • •Nowo zdiagnozowana ostra białaczka limfoblastyczna typu T.
  • •Posiadanie niektórych zespołów genetycznych (np. zespół Downa, zespół Blooma).
  • •Ostra białaczka/chłoniak Burkitta.
  • •Problemy z sercem, które mogą utrudniać leczenie (np. niewydolność serca, zaburzenia rytmu serca).
  • •Brak zgody pacjenta (lub jego opiekuna prawnego) na udział w badaniu.

Simplified criteria — AI translation

Trial details

Minimum age
1 Year
Maximum age
9 Years
Last updated (source)
July 29, 2026
Sex
No restrictions

Therapies / drugs in trial

induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal MethotrexateConsolidation: Vincristine, Mecaptopurine, Intrathecal MethotrexateConsolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal MethotrexateInterim Maintenance(IM): Vincristine, Methotrexate, Intrathecal MethotrexateInterim Maintenance(IM): Vincristine, Methotrexate, Mercaptopurine, Intrathecal MethotrexateDelayed Intesification(DI): Vincristine, Mercaptopurine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal MethotrexateDelayed Intesification(DI): Vincristine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal MethotrexateMaintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate

Locations (13)

Asan Medical Center

Seoul, South Korea

Samsung Medical Center

Seoul, South Korea

Pusan National University Yangsan Hospital

Yangsan, South Korea

Kyungpook National University Chilgok-Hospital

Daegu, South Korea

Chungnam National University Hospital

Daejeon, South Korea

Chonnam National University Hwasun Hospital

Hwasun, South Korea

Jeju National University Hospital

Jeju City, South Korea

Seoul National University Bundang Hospital

Seongnam, South Korea

Korea University Anam Hospital

Seoul, South Korea

Seoul National University Hospital

Seoul, South Korea

Severance Hospital

Seoul, South Korea

Seoul saint Mary's Hospital

Seoul, South Korea

Ajou University Medical Center

Suwon, South Korea

Trial contact

Hee Young Ju, MD, Phd

heeyoung.ju@samsung.com82-2-3410-0865

hyunjung Shin

hjds.shin@samsung.com82-2-3410-6763

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Open original on ClinicalTrials.gov ↗Have questions? Contact us

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/31/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.